Trials / Unknown
UnknownNCT06068556
Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)
Safety, Reactogenicity and Immunogenicity Study of the Vector Vaccine GamCovidVac-M for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Composition With Participation of 12-17 Years Old Volunteers.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · Academic / Other
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac-M for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of 12-17 years old volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition | Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II. |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2023-10-05
- Last updated
- 2023-10-05
Source: ClinicalTrials.gov record NCT06068556. Inclusion in this directory is not an endorsement.